ReCode Announces First Participants Dosed in a Phase 1 Study of RCT2100
ReCode Therapeutics to Participate in February Conferences
Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration
As green shoots slowly push from the scorched Earth biotech markets, ReCode Therapeutics CEO Shehnaaz Suliman, M.D., is watching closely, biding her time for a potential second half IPO.
ReCode Doses First Patient in Phase 1 Clinical Study of Novel mRNA-based Therapy
ReCode Therapeutics to Participate in November Conferences
ReCode Therapeutics Announces Closing of Extension to Series B Financing
ReCode Therapeutics to Present at September Investor Conferences
MENLO PARK, Calif.--(BUSINESS WIRE)--ReCode Therapeutics, a clinical-stage genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics, announced today the appointment of Erica Jefferson as senior vice president of corporate affairs. In this newly created role, Ms. Jefferson will be responsible for the strategic leadership, development, and management of ReCode’s external and employee communications initiatives, including media, investor, and stakeholder engagement. She will report directly to Shehnaaz Suliman, M.D., MBA, M.Phil., chief executive officer, ReCode Therapeutics.
MENLO PARK, Calif.--(BUSINESS WIRE)--ReCode Therapeutics, a genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics, today announced that Angèle Maki, Ph.D., Senior Vice President, Business Development of ReCode Therapeutics, will present a company overview at 8:30 a.m. ET on Friday, June 9, 2023 at the Jefferies Healthcare Conference being held in New York, NY.